| Immune Deficiency Foundation

Home

Xolremdi

Mavorixafor.
Approved to treat: Warts, hypogammaglobulinemia, immunodeficiency, myelokathexis (WHIM) syndrome.
Ages: 12+

Report side effects/adverse events at 1-866-MED-X4MI (1-866-633-9464).

Package Insert Product website Copay assistance

Elias cheering

Family advocates for son with NEMO

Person using pen and clipboard to fill out paperwork.

Autoimmune diagnoses may obscure primary immunodeficiency

Title slide for 2023 National Patient Survey report.

2023 National Patient Survey report

Two ambulances parked outside of a hospital emergency room.

¡Estoy inmunodeprimido! tarjeta de emergencia

Ver formato de documento portátil

School nurse holds stethoscope to child's heart

School nurses aid in care of children with primary immunodeficiency

woman and child gardening

Spring 2024 IDF ADVOCATE newsletter

Three doctors huddled in a discussion

Primary immunodeficiency education series boosts knowledge

Ask the expert: PI and fatigue

Listen to podcast

Y-shaped antibody molecule.

New COVID-19 preventative Pemgarda authorized for immunocompromised

Immune Deficiency Foundation
7550 Teague Road, Suite 220
Hanover, Maryland 21076

P: 410-321-6647